133 related articles for article (PubMed ID: 23026925)
1. C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile infection.
Farne HA; Martin NK; Main J; Orchard T; Tyrrell-Price J
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):33-6. PubMed ID: 23026925
[TBL] [Abstract][Full Text] [Related]
2. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.
Jardin CG; Palmer HR; Shah DN; Le F; Beyda ND; Jiang Z; Garey KW
J Hosp Infect; 2013 Sep; 85(1):28-32. PubMed ID: 23834988
[TBL] [Abstract][Full Text] [Related]
3. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older.
Cober ED; Malani PN
J Am Geriatr Soc; 2009 Apr; 57(4):659-62. PubMed ID: 19392957
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin in the treatment of recurrent Clostridium difficile infection.
Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ
Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of Clostridium difficile infection.
Dupont HL
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
[TBL] [Abstract][Full Text] [Related]
6. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.
Pépin J; Valiquette L; Alary ME; Villemure P; Pelletier A; Forget K; Pépin K; Chouinard D
CMAJ; 2004 Aug; 171(5):466-72. PubMed ID: 15337727
[TBL] [Abstract][Full Text] [Related]
7. Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy.
Tieu JD; Schmidt SA; Miller JL; Kupiec KE; Skrepnek GH; Liu C; Smith WJ
J Oncol Pharm Pract; 2019 Apr; 25(3):520-528. PubMed ID: 29157145
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
[TBL] [Abstract][Full Text] [Related]
9. Assessment of 30-day all-cause mortality in metronidazole-treated patients with Clostridium difficile infection.
Venugopal AA; Szpunar S; Sanchez K; Sessions R; Johnson LB
Scand J Infect Dis; 2013 Oct; 45(10):786-90. PubMed ID: 23746336
[TBL] [Abstract][Full Text] [Related]
10. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
Tart SB
J Pharm Pract; 2013 Oct; 26(5):488-90. PubMed ID: 23940121
[TBL] [Abstract][Full Text] [Related]
11. Clostridium difficile disease and vancomycin--questionable clinical superiority.
Tarchini G
Clin Infect Dis; 2011 Jul; 53(2):212. PubMed ID: 21690637
[No Abstract] [Full Text] [Related]
12. Treatment of Clostridium difficile disease in patients not responding to metronidazole.
Kapoor S
J Infect; 2008 May; 56(5):394-5. PubMed ID: 18410968
[No Abstract] [Full Text] [Related]
13. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea.
McPherson S; Rees CJ; Ellis R; Soo S; Panter SJ
Dis Colon Rectum; 2006 May; 49(5):640-5. PubMed ID: 16525744
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with failure of metronidazole in Clostridium difficile-associated disease.
Fernandez A; Anand G; Friedenberg F
J Clin Gastroenterol; 2004; 38(5):414-8. PubMed ID: 15100520
[TBL] [Abstract][Full Text] [Related]
16. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
Parmar SR; Bhatt V; Yang J; Zhang Q; Schuster M
J Oncol Pharm Pract; 2014 Jun; 20(3):172-82. PubMed ID: 23804627
[TBL] [Abstract][Full Text] [Related]
17. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
18. Clostridium difficile Infection and Patient-Specific Antimicrobial Resistance Testing Reveals a High Metronidazole Resistance Rate.
Barkin JA; Sussman DA; Fifadara N; Barkin JS
Dig Dis Sci; 2017 Apr; 62(4):1035-1042. PubMed ID: 28116592
[TBL] [Abstract][Full Text] [Related]
19. [Left-sided ulcerative colitis reactivated and aggravated during clostridium difficile infection].
Na DK; Kim JB; Shin YC; Shin SL; Kim HJ; Baek IH; Park SH; Lee MS
Korean J Gastroenterol; 2011 Jun; 57(6):374-8. PubMed ID: 21694491
[TBL] [Abstract][Full Text] [Related]
20. Clinical inquiries. What are effective therapies for Clostridium difficile-associated diarrhea?
Ohl ME; Stevermer JJ; Meadows S; Tribuna J; Chek K
J Fam Pract; 2005 Feb; 54(2):176-8. PubMed ID: 15689297
[No Abstract] [Full Text] [Related]
[Next] [New Search]
